Phase I/II clinical trial of combined pre-irradiation with pemetrexed and erlotinib followed by maintenance erlotinib for recurrent and second primary squamous cell carcinoma of the head and neck

Trial Profile

Phase I/II clinical trial of combined pre-irradiation with pemetrexed and erlotinib followed by maintenance erlotinib for recurrent and second primary squamous cell carcinoma of the head and neck

Discontinued
Phase of Trial: Phase I/II

Latest Information Update: 20 Apr 2017

At a glance

  • Drugs Erlotinib (Primary) ; Pemetrexed (Primary)
  • Indications Head and neck cancer
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 30 Aug 2016 Status changed from recruiting to discontinued.
    • 30 Aug 2016 Status changed from recruiting to discontinued.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top